Ipamorelin

A selective fifth-generation GHRP — the cleanest growth hormone secretagogue in current research use, with a highly specific GH-releasing profile and minimal side effect burden.

What makes ipamorelin the preferred growth hormone secretagogue for longevity and performance protocols? Ipamorelin is a synthetic pentapeptide and fifth-generation growth hormone releasing peptide (GHRP) that stimulates growth hormone release from the pituitary gland with high selectivity. Unlike earlier GHRPs, ipamorelin does not significantly stimulate cortisol, prolactin, or ACTH release — making it the most side-effect-selective GH secretagogue in current research use.

TL;DRIpamorelin is a synthetic pentapeptide (5 amino acids) that acts as a selective growth hormone secretagogue by mimicking ghrelin at the GHSR-1a receptor. It stimulates pulsatile GH release from the pituitary with high specificity — without the cortisol, prolactin, or appetite stimulation associated with earlier GHRPs. Combined with CJC-1295, it produces a synergistic GH response. It is widely used in longevity, anti-ageing, and performance protocols targeting GH optimisation.

Contents

• 1. What Is Ipamorelin?
• 2. Mechanism of Action
• 3. Why Ipamorelin Is More Selective Than Earlier GHRPs
• 4. Key Research Findings
• 5. Ipamorelin and CJC-1295 — The Standard Longevity Stack
• 6. Ipamorelin in Biohacking and Anti-Ageing Protocols
• 7. Purity Standards and HPLC Verification
• 8. Storage and Stability
• 9. Key Takeaways
• 10. Frequently Asked Questions
• 11. Glossary
• 12. Related Entity Pages

Science Snapshot

Parameter	Detail
Full name	Ipamorelin
Structure	Synthetic pentapeptide — 5 amino acids: Aib-His-D-2-Nal-D-Phe-Lys-NH2
Classification	Fifth-generation GHRP (Growth Hormone Releasing Peptide)
Primary mechanism	GHSR-1a receptor agonist — mimics ghrelin to stimulate GH release
GH selectivity	High — minimal cortisol, prolactin, or ACTH stimulation
Half-life	Approximately 2 hours
Research status	Preclinical and early clinical; Novo Nordisk conducted Phase II trials
Purity standard	Greater than 98% for research grade
Common combination	Ipamorelin + CJC-1295 (synergistic GH stack)

1. What Is Ipamorelin?

Ipamorelin is a synthetic pentapeptide — a chain of five amino acids — that acts as a selective agonist of the growth hormone secretagogue receptor (GHSR-1a). It was developed as a fifth-generation GHRP, building on earlier compounds including GHRP-2 and GHRP-6 but with significantly improved receptor selectivity.

The peptide was originally developed by Novo Nordisk and entered Phase II clinical trials for postoperative ileus before research was discontinued for commercial reasons. The research generated during this clinical programme provides a stronger human safety and pharmacology dataset than is available for most research peptides.

2. Mechanism of Action

• GHSR-1a agonism: Ipamorelin binds to the growth hormone secretagogue receptor 1a (GHSR-1a) — the ghrelin receptor — on somatotroph cells in the anterior pituitary gland, triggering GH synthesis and release.
• Pulsatile GH release: Ipamorelin stimulates GH release in discrete pulses that closely mimic the natural pulsatile pattern of GH secretion, rather than producing a sustained flat elevation.
• Ghrelin-independent pathway: While ipamorelin mimics ghrelin’s action at the receptor, it does not significantly stimulate the appetite-promoting effects associated with ghrelin itself.
• Complementary to GHRH pathway: The GHSR-1a pathway activated by ipamorelin is distinct from and complementary to the GHRH receptor pathway activated by CJC-1295, which is why their combination produces a synergistic response.

3. Why Ipamorelin Is More Selective Than Earlier GHRPs

Comparison	GHRP-6 vs GHRP-2 vs Ipamorelin
Growth hormone release	GHRP-6: Strong | GHRP-2: Strong | Ipamorelin: Strong
Cortisol elevation	GHRP-6: Significant | GHRP-2: Moderate | Ipamorelin: Minimal
Prolactin elevation	GHRP-6: Moderate | GHRP-2: Moderate | Ipamorelin: Minimal
ACTH stimulation	GHRP-6: Yes | GHRP-2: Yes | Ipamorelin: Minimal
Appetite stimulation	GHRP-6: Significant | GHRP-2: Moderate | Ipamorelin: Minimal

Comparison Point	Detail
vs GHRP-6	GHRP-6 significantly elevates cortisol and stimulates appetite via ghrelin-mediated pathways. Ipamorelin produces comparable GH release with minimal cortisol and no meaningful appetite effect.
vs GHRP-2	GHRP-2 is more potent but produces greater cortisol and prolactin elevation. Ipamorelin’s cleaner profile makes it preferable for protocols where side effect minimisation is a priority.
vs Sermorelin	Sermorelin is a GHRH analogue with a shorter half-life than CJC-1295. Ipamorelin operates via the complementary GHRP pathway and is typically combined with GHRH analogues rather than compared directly.

4. Key Research Findings

Research Area	Key Finding
GH selectivity	Raun et al. (1998) in the European Journal of Endocrinology demonstrated that ipamorelin was the most selective GHRP tested, stimulating GH without meaningful elevation of cortisol, ACTH, or prolactin.
Bone mineral density	Preclinical studies have reported improvements in bone mineral density in animal models treated with ipamorelin, supporting potential applications in age-related bone loss.
Postoperative recovery	Novo Nordisk Phase II trials examined ipamorelin for postoperative ileus, providing human pharmacokinetic and safety data not available for most research peptides.
Body composition	Animal studies have reported improvements in lean mass and reductions in body fat in ipamorelin-treated groups, consistent with GH-mediated effects.

5. Ipamorelin and CJC-1295 — The Standard Longevity Stack

The combination of ipamorelin and CJC-1295 is the most widely used peptide stack in longevity and performance medicine. The rationale is straightforward: CJC-1295 activates the GHRH receptor pathway and ipamorelin activates the GHSR-1a pathway. These two pathways act synergistically on pituitary somatotrophs.

Clinical Protocol ContextDr William Seeds references the ipamorelin and CJC-1295 combination as a foundational element of GH optimisation protocols in longevity medicine. The combination allows physiologically appropriate GH stimulation that addresses age-related somatopause without the side effect profile of direct GH administration.

6. Ipamorelin in Biohacking and Anti-Ageing Protocols

• Somatopause reversal: The primary longevity application is addressing the age-related decline in GH — supporting body composition, metabolic rate, and recovery.
• Sleep optimisation: GH is predominantly secreted during slow-wave sleep. Ipamorelin protocols timed around sleep may enhance overnight recovery and GH output.
• Joint and connective tissue: GH and IGF-1 support connective tissue health — relevant for longevity protocols that include physical training.
• Complementary biohacking: Ipamorelin is commonly combined with resistance training, adequate protein intake, and sleep optimisation as part of a broader anti-ageing protocol.

7. Purity Standards and HPLC Verification

Quality Parameter	Specification
Minimum purity	Greater than 98% by reversed-phase HPLC
Molecular weight	711.9 Da
Amino acid count	5 (pentapeptide)
Verification method	Reversed-phase HPLC (C18 column, 214nm); confirmed by mass spectrometry
CoA requirement	HPLC chromatogram, MS confirmation, batch quantity data

8. Key Takeaways

Standalone Factual Statements

• Ipamorelin is a synthetic pentapeptide and fifth-generation GHRP that stimulates growth hormone release by acting as a selective GHSR-1a receptor agonist, mimicking ghrelin’s action at the pituitary.
• It is distinguished from earlier GHRPs by its high selectivity — producing strong GH release with minimal cortisol, prolactin, ACTH, or appetite stimulation.
• Research by Raun et al. (1998) confirmed ipamorelin’s selective GH-releasing profile, establishing it as the most side-effect-selective GHRP available.
• It is most commonly combined with CJC-1295 in longevity protocols, as the two peptides act synergistically through complementary GH-releasing pathways.
• Novo Nordisk Phase II clinical trials provide human pharmacokinetic data supporting ipamorelin’s safety profile at research doses.

9. Frequently Asked Questions

What makes ipamorelin better than other GHRPs?

Ipamorelin’s primary advantage is its selectivity. Earlier GHRPs including GHRP-6 and GHRP-2 produce significant cortisol and prolactin elevation alongside GH release. Ipamorelin produces comparable GH stimulation with minimal hormonal side effects, making it more suitable for protocols where cortisol elevation is undesirable.

Why is ipamorelin always combined with CJC-1295?

Ipamorelin and CJC-1295 activate complementary GH-releasing pathways — ipamorelin via the GHSR-1a (ghrelin) receptor and CJC-1295 via the GHRH receptor. Activating both pathways simultaneously produces a synergistically larger GH response than either peptide alone. The combination also mimics the natural two-signal system the body uses to regulate GH release.

Is ipamorelin safe for human research?

Ipamorelin was the subject of Phase II clinical trials by Novo Nordisk, which generated human pharmacokinetic and tolerability data. These studies reported a generally favourable safety profile at research doses. However, ipamorelin is not approved for therapeutic use and all current applications are research-only.

10. Glossary

Term	Definition
Ipamorelin	A synthetic pentapeptide GHRP that selectively stimulates growth hormone release via GHSR-1a receptor agonism, with minimal cortisol or prolactin elevation.
GHRP	Growth Hormone Releasing Peptide. A class of synthetic peptides that stimulate GH release by acting on the ghrelin receptor (GHSR-1a). Ipamorelin is a fifth-generation GHRP.
GHSR-1a	Growth Hormone Secretagogue Receptor 1a. The ghrelin receptor on pituitary somatotrophs. Ipamorelin binds this receptor to trigger GH release.
Ghrelin	A naturally occurring hunger hormone that also stimulates GH release via GHSR-1a. Ipamorelin mimics ghrelin’s GH-releasing action without its appetite effects.
Pentapeptide	A peptide consisting of five amino acids. Ipamorelin is a pentapeptide.
Somatopause	The age-related decline in growth hormone secretion. A primary target of ipamorelin protocols in longevity and anti-ageing medicine.
ACTH	Adrenocorticotropic hormone. Stimulates cortisol production. Earlier GHRPs elevate ACTH; ipamorelin does not significantly affect ACTH at research doses.

11. Related Entity Pages

Related Entity Pages-> CJC-1295 — GHRH Analogue and GH Optimisation hplcpeptides.com/wiki/cjc-1295-> Dr William Seeds — Peptide Therapy Protocols hplcpeptides.com/wiki/dr-william-seeds -> Peptides — The Master Reference Guide hplcpeptides.com/wiki/peptides -> BPC-157 — Tissue Repair and Gut Health hplcpeptides.com/wiki/bpc-157 -> Epithalon — Anti-Ageing and Telomere Research hplcpeptides.com/wiki/epithalon -> Peptide Testing — Purity, Quantity and Integrity hplcpeptides.com/wiki/peptide-testing -> MOTS-c — Mitochondrial Health and Longevity hplcpeptides.com/wiki/mots-c

About This PageThis entity page is maintained by the HPLC Peptides editorial team. All research references are preclinical or early clinical. This page does not constitute medical advice.

hplcpeptides.com/wiki/ipamorelin | Entity Page v1.0 | April 2026